Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has been given a consensus rating of “Buy” by the eight analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $32.80.
Several research firms recently weighed in on EIGR. ValuEngine raised shares of Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Wedbush reaffirmed a “buy” rating on shares of Eiger BioPharmaceuticals in a research note on Wednesday, October 25th. Oppenheimer Holdings, Inc. set a $34.00 target price on shares of Eiger BioPharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Roth Capital assumed coverage on shares of Eiger BioPharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $35.00 target price for the company. Finally, Zacks Investment Research lowered shares of Eiger BioPharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th.
Eiger BioPharmaceuticals (NASDAQ EIGR) opened at $10.70 on Thursday. Eiger BioPharmaceuticals has a 52 week low of $6.10 and a 52 week high of $13.95. The company has a quick ratio of 5.78, a current ratio of 5.78 and a debt-to-equity ratio of 1.19.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.28) by $0.18. research analysts expect that Eiger BioPharmaceuticals will post -4.96 earnings per share for the current fiscal year.
In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn acquired 15,000 shares of the stock in a transaction on Friday, September 1st. The stock was acquired at an average price of $9.53 per share, for a total transaction of $142,950.00. Following the completion of the transaction, the director now directly owns 31,355 shares of the company’s stock, valued at $298,813.15. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.80% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the business. Wedbush Securities Inc. bought a new position in Eiger BioPharmaceuticals during the third quarter valued at $114,000. JPMorgan Chase & Co. lifted its position in Eiger BioPharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 8,748 shares during the last quarter. OxFORD Asset Management LLP bought a new position in Eiger BioPharmaceuticals during the third quarter valued at $147,000. Bank of New York Mellon Corp lifted its position in Eiger BioPharmaceuticals by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 13,696 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 614 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new position in Eiger BioPharmaceuticals during the second quarter valued at $114,000. Institutional investors and hedge funds own 61.04% of the company’s stock.
WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/16/eiger-biopharmaceuticals-inc-eigr-receives-average-recommendation-of-buy-from-brokerages.html.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.